AGS-8M4 + Pegylated liposomal doxorubicin (PLD) + gemcitabine + carboplatin
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma
Conditions
Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
Trial Timeline
Oct 1, 2009 → Apr 1, 2010
NCT ID
NCT01016054About AGS-8M4 + Pegylated liposomal doxorubicin (PLD) + gemcitabine + carboplatin
AGS-8M4 + Pegylated liposomal doxorubicin (PLD) + gemcitabine + carboplatin is a phase 1 stage product being developed by Astellas Pharma for Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01016054. Target conditions include Carcinoma, Ovarian Cancer, Ovarian Diseases.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01016054 | Phase 1 | Terminated |
Competing Products
20 competing products in Carcinoma